Protocol I199911: A PHASE I CLINICAL TRIAL OF mTOR INHIBITION WITH SIROLIMUS FOR ENHANCING ALVAC(2)-NY-ESO1(M)/TRICOM VACCINE INDUCED ANTI-TUMOR IMMUNITY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER Kunle Odu

Source URL: osp.od.nih.gov

• Medicine
• Cancer vaccine
• Sirolimus
• Ovarian cancer
• T helper cell
• Mammalian target of rapamycin
• Breast cancer treatment
• Biology
• T cells
• Immune system